Cummings Keith Lamont 4
4 · PLIANT THERAPEUTICS, INC. · Filed Jan 26, 2026
Research Summary
AI-generated summary of this filing
Pliant Therapeutics CFO Keith Cummings Receives 400,000-Share Award
What Happened
Keith Lamont Cummings, Chief Financial Officer of Pliant Therapeutics (PLRX), received a derivative equity award for 400,000 shares on 2026-01-22. The filing lists a $0.00 price for the award (no cash paid reported). The grant is a vesting/option-type award (see footnote) rather than an open-market purchase or sale.
Key Details
- Transaction date: 2026-01-22; Form 4 filed 2026-01-26 (appears to be filed on time).
- Reported transaction: Grant/award (derivative) of 400,000 shares; price shown $0.00.
- Vesting: Footnote states 1/48th of the shares vest and become exercisable in substantially equal monthly installments beginning January 1, 2026, subject to continued service.
- Shares owned after transaction: Not specified in the details provided.
- No indication this was a sale; it's an equity grant to an executive.
Context
This is a standard equity compensation grant to an executive (derivative award that vests monthly over four years). Such grants align executive and shareholder interests but are not direct purchases of stock on the open market; they typically do not by themselves indicate buying or selling sentiment.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-01-22+400,000→ 400,000 totalExercise: $1.30Exp: 2036-01-22→ Common Stock (400,000 underlying)
Footnotes (1)
- [F1]1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.